▲ +93.55% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Inozyme Pharma in the last 3 months. The average price target is $36.00, with a high forecast of $40.00 and a low forecast of $33.00. The average price target represents a 93.55% upside from the last price of $18.60.
The current consensus among 4 polled investment analysts is to buy stock in Inozyme Pharma.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.